MultiStem Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)

MultiStem is an allogeneic, regenerative medicine advanced therapy indicated for treatment of acute ischemic stroke within 36 hours after symptom onset.

The primary objective of this study is to evaluate the efficacy of MultiStem on functional outcome in subjects with ischemic stroke. This is a pivotal Phase 3, randomized, double-blind, placebo-controlled, multicenter international study. The total study duration for safety follow-up will be 12 months.

Approximately 300 subjects who have experienced an acute cortical ischemic stroke and fulfill all the eligibility criteria will be enrolled into the study globally.